1
Clinical Trials associated with Virus Activated Killer immune Cells (Binhui Bio)An Open Label, Randomized Controlled Clinical Study on the Safety and Efficacy of Virus Activated Killer Immune Cells (VAK) in the Treatment of Malignant Pleural and Peritoneal Effusion
Theory of VAK:
Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells. They could be restimulated by virus antigen, and play a powerful tumor killing role while intrapleural to subjects.
Releasing of tumor-associated antigen could induce specific anti-tumor immune response.
Preparation of VAK:
Separate the immune cells and tumor cells from Malignant Pleural and Peritoneal Effusion.
Incubate the immune cells with inactivated viruses and tumor cells.
Wash to remove impurities.
Intrapleural the immune cells to patients
100 Clinical Results associated with Virus Activated Killer immune Cells (Binhui Bio)
100 Translational Medicine associated with Virus Activated Killer immune Cells (Binhui Bio)
100 Patents (Medical) associated with Virus Activated Killer immune Cells (Binhui Bio)
100 Deals associated with Virus Activated Killer immune Cells (Binhui Bio)